Literature DB >> 23686488

Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment.

Seema Rawal1, Fuliang Chu, Min Zhang, Hyun Jun Park, Durga Nattamai, Shibichakravarthy Kannan, Rakesh Sharma, David Delgado, Tina Chou, Heather Y Lin, Veerabhadran Baladandayuthapani, Amber Luong, Francisco Vega, Nathan Fowler, Chen Dong, R Eric Davis, Sattva S Neelapu.   

Abstract

The microenvironment of human follicular lymphoma (FL), an incurable B cell non-Hodgkin's lymphoma, is thought to play a major role in its pathogenesis and course. Microenvironmental cells of likely importance include follicular Th cells (TFH) and regulatory T cells (Tregs), and understanding their interactions with FL tumor cells is necessary to develop novel therapeutic strategies. We found that IL-4 and CD40L are expressed by intratumoral TFH and induce production of CCL17 and CCL22 by FL tumor cells. IL-4 alone induces only CCL17 but enhances stimulation by CD40L of both CCL17 and CCL22. Consistent with our in vitro results, mRNA transcripts of IL-4 correlated with CCL17, but not CCL22, in gene expression profiling studies of FL biopsies, whereas CD40L correlated with both CCL17 and CCL22. Tumor supernatants induced preferential migration of Tregs and IL-4-producing T cells rather than IFN-γ-producing T cells, and Abs to CCR4 significantly abrogated the migration of Tregs. Our results suggest that through two distinct mechanisms, intratumoral TFH induce production of CCL17 and CCL22 by FL tumor cells and facilitate active recruitment of Tregs and IL-4-producing T cells, which, in turn, may stimulate more chemokine production in a feed-forward cycle. Thus, TFH appear to play a major role in generating an immunosuppressive tumor microenvironment that promotes immune escape and tumor survival and growth. Our results provide novel insights into the cross talk among TFH, tumor cells, and Tregs in FL, and offer potential targets for development of therapeutic strategies to overcome immune evasion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23686488      PMCID: PMC3680117          DOI: 10.4049/jimmunol.1201363

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells.

Authors:  P Amé-Thomas; J Le Priol; H Yssel; G Caron; C Pangault; R Jean; N Martin; T Marafioti; P Gaulard; T Lamy; T Fest; G Semana; K Tarte
Journal:  Leukemia       Date:  2011-10-21       Impact factor: 11.528

2.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

Authors: 
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

3.  The natural history of initially untreated low-grade non-Hodgkin's lymphomas.

Authors:  S J Horning; S A Rosenberg
Journal:  N Engl J Med       Date:  1984-12-06       Impact factor: 91.245

4.  Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro.

Authors:  J L Schultze; M J Seamon; S Michalak; J G Gribben; L M Nadler
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

5.  TARC and MDC are produced by CD40 activated human B cells and are elevated in the sera of infantile atopic dermatitis patients.

Authors:  Lin Lin; Shigeaki Nonoyama; Akihiro Oshiba; Yasuhiro Kabasawa; Shuki Mizutani
Journal:  J Med Dent Sci       Date:  2003-03

6.  BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases.

Authors:  G Dölken; G Illerhaus; C Hirt; R Mertelsmann
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

7.  Involvement of the bcl-2 gene in human follicular lymphoma.

Authors:  Y Tsujimoto; J Cossman; E Jaffe; C M Croce
Journal:  Science       Date:  1985-06-21       Impact factor: 47.728

8.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18).

Authors:  T J McDonnell; S J Korsmeyer
Journal:  Nature       Date:  1991-01-17       Impact factor: 49.962

9.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

Review 10.  The role of interleukin 13 in classical Hodgkin lymphoma.

Authors:  Brian F Skinnider; Ursula Kapp; Tak W Mak
Journal:  Leuk Lymphoma       Date:  2002-06
View more
  35 in total

1.  Elucidation and Pharmacological Targeting of Novel Molecular Drivers of Follicular Lymphoma Progression.

Authors:  Brygida Bisikirska; Mukesh Bansal; Yao Shen; Julie Teruya-Feldstein; Raju Chaganti; Andrea Califano
Journal:  Cancer Res       Date:  2015-11-20       Impact factor: 12.701

Review 2.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

3.  Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder.

Authors:  Benjamin Kaffenberger; Brad Haverkos; Kelly Tyler; Henry K Wong; Pierluigi Porcu; Alejandro Ariel Gru
Journal:  Am J Dermatopathol       Date:  2015-08       Impact factor: 1.533

Review 4.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 5.  Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach.

Authors:  Kirsten M Boughan; Paolo F Caimi
Journal:  Curr Oncol Rep       Date:  2019-05-23       Impact factor: 5.075

6.  Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

Authors:  Jason R Westin; Fuliang Chu; Min Zhang; Luis E Fayad; Larry W Kwak; Nathan Fowler; Jorge Romaguera; Fredrick Hagemeister; Michelle Fanale; Felipe Samaniego; Lei Feng; Veerabhadran Baladandayuthapani; Zhiqiang Wang; Wencai Ma; Yanli Gao; Michael Wallace; Luis M Vence; Laszlo Radvanyi; Tariq Muzzafar; Rinat Rotem-Yehudar; R Eric Davis; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2013-12-11       Impact factor: 41.316

Review 7.  Role of the microenvironment across histological subtypes of NHL.

Authors:  Karin Tarte
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Authors:  Matthew J Frank; Patrick M Reagan; Nancy L Bartlett; Leo I Gordon; Jonathan W Friedberg; Debra K Czerwinski; Steven R Long; Richard T Hoppe; Robert Janssen; Albert F Candia; Robert L Coffman; Ronald Levy
Journal:  Cancer Discov       Date:  2018-08-28       Impact factor: 39.397

9.  Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.

Authors:  Kui Shin Voo; Myriam Foglietta; Elena Percivalle; Fuliang Chu; Durga Nattamai; Megan Harline; Seung-Tae Lee; Laura Bover; Heather Y Lin; Veerabhadran Baladandayuthapani; David Delgado; Amber Luong; R Eric Davis; Larry W Kwak; Yong-Jun Liu; Sattva S Neelapu
Journal:  Int J Cancer       Date:  2014-05-12       Impact factor: 7.396

10.  Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.

Authors:  Ricardo García-Muñoz; Ascensión López-Díaz-de-Cerio; Jesus Feliu; Angel Panizo; Pilar Giraldo; Mercedes Rodríguez-Calvillo; Carlos Grande; Esther Pena; Mayte Olave; Carlos Panizo; Susana Inogés
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.